资讯

Sarepta says it won't comply with FDA request to stop shipping gene therapy Elevidys
U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a ...
Exclusive: US FDA to ask Sarepta to stop shipments of gene therapy Elevidys, source says
The U.S. Food and Drug Administration is planning to ask Sarepta Therapeutics to voluntarily stop all shipments of its gene ...
华尔街见闻 on MSN2 天
美国FDA：要求Sarepta Therapeutics暂停分销Elevidys，但被拒绝
美国食品药品管理局（FDA）要求Sarepta Therapeutics Inc.（SRPT）暂停分销Elevidys。 要求该公司暂停Elevidys临床试验。 研究的受试对象可能会面临不合理的风险。 该公司拒绝自愿停止发货Elevidys。
Gene therapy maker Sarepta tells FDA it won’t halt shipments despite patient deaths
Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...
Leerink Partners因FDA担忧和可信度问题下调Sarepta股票评级
Investing.com - Leerink Partners将Sarepta Therapeutics (NASDAQ: SRPT )的评级从"跑赢大盘"下调至"与大盘持平"，并将目标价从45.00美元大幅下调至10.00美元。该股在过去一年已经损失了超过90%的价值，目前交易价格接近其52周低点12.81美元。根据 InvestingPro 数据，该公司市值已降至13.8亿美元。
Sarepta tells FDA it won’t halt shipments despite patient deaths
In a highly unusual move, Cambridge-based Sarepta said late Friday won’t comply with a request from the Food and Drug ...
德意志银行将Sarepta股票评级下调至卖出，因安全问题担忧
Investing.com - 德意志银行周一将Sarepta Therapeutics (NASDAQ:SRPT)的评级从持有下调至卖出，并将目标价从25.00美元大幅削减至9.00美元，此举是基于该生物科技公司一系列负面发展。根据InvestingPro数据，该公司股票年初至今已下跌超过88%，目前市值为13.8亿美元。 据德意志银行报道，此次评级下调发生在Sarepta股价周五暴跌37%之际 ...
Sarepta’s Risky Gamble: Gene Therapy Stays on Market Despite FDA Request
When three patients die after taking a cutting-edge drug, most companies hit the brakes. Not Sarepta Therapeutics. The ...
Sarepta Refused FDA’s Request to Halt Elevidys Shipments
The Food and Drug Administration plans to ask Sarepta Therapeutics Inc. to pause shipments of its Elevidys treatment after ...
Sarepta to continue Elevidys shipments despite FDA request to halt
Sarepta (SRPT) plans to continue Elevidys shipments for Duchenne muscular dystrophy, despite FDA request not to do so after ...
美国食品药品管理局（FDA）要求Sarepta Therapeutics Inc.（SRPT）暂停分销 ...
美国食品药品管理局（FDA）要求Sarepta Therapeutics Inc.（SRPT）暂停分销Elevidys。要求该公司暂停Elevidys临床试验。研究的受试对象可能会面临不合理的风险。该公司拒绝自愿停止发货Elevidys。 返回搜狐，查看更多 ...
Sarepta Therapeutics laying off 80 employees in Ohio
Sarepta Therapeutics to lay off 493 workers, including 80 in Ohio, amid FDA probe, stock plunge, and concerns over Duchenne ...